JP2011520983A - オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム - Google Patents

オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム Download PDF

Info

Publication number
JP2011520983A
JP2011520983A JP2011510720A JP2011510720A JP2011520983A JP 2011520983 A JP2011520983 A JP 2011520983A JP 2011510720 A JP2011510720 A JP 2011510720A JP 2011510720 A JP2011510720 A JP 2011510720A JP 2011520983 A JP2011520983 A JP 2011520983A
Authority
JP
Japan
Prior art keywords
oligonucleotide
compound
independently
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520983A5 (cg-RX-API-DMAC7.html
Inventor
チャオ,ホン
レディ,プラサナ
Original Assignee
エンゾン ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンゾン ファーマシューティカルズ,インコーポレーテッド filed Critical エンゾン ファーマシューティカルズ,インコーポレーテッド
Publication of JP2011520983A publication Critical patent/JP2011520983A/ja
Publication of JP2011520983A5 publication Critical patent/JP2011520983A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011510720A 2008-05-23 2009-05-22 オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム Pending JP2011520983A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5595008P 2008-05-23 2008-05-23
US5586908P 2008-05-23 2008-05-23
US61/055,950 2008-05-23
US61/055,869 2008-05-23
US10657808P 2008-10-19 2008-10-19
US10657608P 2008-10-19 2008-10-19
US61/106,576 2008-10-19
US61/106,578 2008-10-19
PCT/US2009/044953 WO2009143412A2 (en) 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides

Publications (2)

Publication Number Publication Date
JP2011520983A true JP2011520983A (ja) 2011-07-21
JP2011520983A5 JP2011520983A5 (cg-RX-API-DMAC7.html) 2012-06-28

Family

ID=41340917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510720A Pending JP2011520983A (ja) 2008-05-23 2009-05-22 オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム

Country Status (6)

Country Link
US (1) US20110105413A1 (cg-RX-API-DMAC7.html)
EP (1) EP2288261A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011520983A (cg-RX-API-DMAC7.html)
CA (1) CA2723263A1 (cg-RX-API-DMAC7.html)
TW (1) TW201004648A (cg-RX-API-DMAC7.html)
WO (1) WO2009143412A2 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721948A2 (pt) * 2007-08-20 2014-04-08 Enzon Pharmaceuticals Inc Ligantes poliméricos contendo frações dissulfeto de piridila
ITMI20131929A1 (it) * 2013-11-20 2015-05-21 Domenico Terenzio Coniugato dell'acido folico e dell'indolo-3-carbinolo per uso medico
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー/エス 環部分にキャリア結合を有するcnpプロドラッグ
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
KR102518217B1 (ko) 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
SI3423103T1 (sl) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases A/S Predzdravila PTH
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
KR102611820B1 (ko) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
JP7039574B2 (ja) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー/エス 放出制御pth化合物の漸増用量設定
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック, インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
US12565525B2 (en) 2018-03-28 2026-03-03 Ascendis Pharma Oncology Division A/S IL-2 conjugates
CA3099620A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
CA3114056A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
CA3114272A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
AU2020205029A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
SG11202104966XA (en) 2019-01-04 2021-06-29 Ascendis Pharma Oncology Div A/S Sustained local drug levels for innate immune agonists
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
SG11202105835YA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
AU2020221491B2 (en) 2019-02-11 2025-02-27 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
CA3143278A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
TW202114738A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
JP2023510790A (ja) 2020-01-13 2023-03-15 アセンディス ファーマ ボーン ディジージズ エー/エス 副甲状腺機能低下症の治療
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
AU2021335032A1 (en) 2020-08-28 2023-03-09 Ascendis Pharma Oncology Division A/S Glycosylated IL-2 proteins and uses thereof
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
EP4314035A1 (en) 2021-04-01 2024-02-07 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
US20240238325A1 (en) * 2021-04-28 2024-07-18 Japan Science And Technology Agency Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same
CN117295528A (zh) * 2021-04-28 2023-12-26 国立研究开发法人科学技术振兴机构 人工核酸以及使用该人工核酸的核酸递送方法
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
JP2024546134A (ja) 2021-12-13 2024-12-17 アセンディス ファーマ オンコロジー ディヴィジョン エー/エス Tlr7/8アゴニストを用いたがん治療
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2023276829A1 (en) 2022-05-23 2024-10-31 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー/エス 2つのpth化合物を含むpth治療レジメン
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
IL323019A (en) 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
EP4676535A1 (en) 2023-03-06 2026-01-14 Ascendis Pharma A/S Multi-albumin binding compounds
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
EP4709423A1 (en) 2023-05-09 2026-03-18 Ascendis Pharma Oncology Division A/S Novel cancer treatments with il-2 conjugates
EP4773987A1 (en) 2023-09-04 2026-07-15 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2026013138A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Compounds with improved albumin-binding
WO2026013136A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding compounds
WO2026013135A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding reagents
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates
WO2026150105A1 (en) 2025-01-13 2026-07-16 Ascendis Pharma A/S Fgf23 degrader conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069388A2 (en) * 2004-12-21 2006-06-29 Nektar Therapeutics Al, Corporation Stabilized polymeric thiol reagents
JP2006517600A (ja) * 2003-01-06 2006-07-27 ネクター セラピューティクス アラバマ,コーポレイション チオール選択的水溶性ポリマー誘導体
WO2008034123A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
WO2008034124A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323048C (en) * 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
AU2002363334A1 (en) * 2001-11-09 2003-05-19 Enzon, Inc. Polymeric thiol-linked prodrugs
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2004230927B9 (en) * 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
MX2009008549A (es) * 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
BRPI0721948A2 (pt) * 2007-08-20 2014-04-08 Enzon Pharmaceuticals Inc Ligantes poliméricos contendo frações dissulfeto de piridila

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517600A (ja) * 2003-01-06 2006-07-27 ネクター セラピューティクス アラバマ,コーポレイション チオール選択的水溶性ポリマー誘導体
WO2006069388A2 (en) * 2004-12-21 2006-06-29 Nektar Therapeutics Al, Corporation Stabilized polymeric thiol reagents
WO2008034123A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
WO2008034124A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers

Also Published As

Publication number Publication date
CA2723263A1 (en) 2009-11-26
WO2009143412A2 (en) 2009-11-26
EP2288261A2 (en) 2011-03-02
US20110105413A1 (en) 2011-05-05
WO2009143412A3 (en) 2010-04-15
EP2288261A4 (en) 2013-09-25
TW201004648A (en) 2010-02-01

Similar Documents

Publication Publication Date Title
WO2009143412A2 (en) Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
JP6522814B2 (ja) オリゴマーおよびオリゴマー・コンジュゲート
CN110290812B (zh) 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
CN102231951A (zh) 用于核酸传递系统的可释放的偶联物
CN117298290A (zh) 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
KR20090055623A (ko) 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커
JP2020537501A (ja) 筋ジストロフィーのためのエクソンスキッピングオリゴマーコンジュゲート
JP2010510810A (ja) ポリマー低分子干渉rna複合体
JP2021526796A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマー
CN104244987A (zh) 新型寡核苷酸缀合物及其应用
JP2021526017A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
CN101534861B (zh) 具有基于位阻酯的生物可降解连接基的聚环氧烷
EP4069261A2 (en) Peptide docking vehicle for targeted nucleic acid delivery
JP7306653B2 (ja) 構造強化されたS-TuDを用いた新規がん治療法
CN113412330A (zh) 用于肌营养不良的外显子跳跃寡聚物缀合物
JP4649408B2 (ja) 「黒色腫阻害活性(mia)」を阻害するアンチセンスオリゴヌクレオチド
JP2021531009A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマー
WO2023198200A1 (zh) 缀合物与组合物及制备方法和用途
JP2012524102A (ja) 7−エチル−10−ヒドロキシカンプトテシンのマルチアームポリマー性コンジュゲートを用いた血管新生の阻害方法
US8110559B2 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
CN116615246A (zh) 包含单取代的同-二价连接基的多缀合物
JP2025512450A (ja) アプタマー、複合体及び組成物並びに製造方法及び使用
CN116801885A (zh) 用于抑制DUX4表达的RNAi试剂、其组合物和使用方法
NZ743588A (en) Exon skipping compositions for treating muscular dystrophy

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20110810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304